15. Innovations in Influenza Vaccines: Strategic Advances in Improving Immunogenicity
Thursday, October 20, 2011: 2:45 PM-4:45 PM
Room: 253ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe promising strategies for improvement of influenza vaccine immunogenicity and efficacy
  • correlate immune responses to influenza vaccines to vaccine efficacy and effectiveness
  • explain the advantages and disadvantages of different influenza vaccine formulations to patients, colleagues, students and other health care personnel

Target Audience: Vaccinologists, Scientists, Researchers, Public Health Practitioners, Pharmacists, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Health Care Workers, Fellows-in-Training, Clinicians, Academicians

Tracks: Pediatric ID, Adult ID

Moderators:  Bruce Gellin, MD, MPH, Department of Health and Human Services and Joanne Langley, MD, Dalhousie University


3:25 PM

4:05 PM
Universal Influenza Vaccines
Robert C. Huebner, PhD

CME Credits: Maximum of 2.0 hours of Category 1 credit possible

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-088-L01-P


B. Gellin, None

J. Langley, sanofi pasteur, glaxosmithkline: Grant Investigator, Research grant

W. Keitel, None

M. Friede, None

R. C. Huebner, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.